Survival of pancreatic cancer cells lacking KRAS function
Name
Muzumdar_et_al-2017-Nature_Communications.pdf
Size
3.95 MB
Format
Adobe PDF
Checksum (MD5)
18640fd18fbc6418d33da76d14e91441
Author(s) • • • • • • • • •
Noll, Elisa M.
Sprick, Martin R.
Trumpp, Andreas
Muzumdar, Mandar
Chen, Pan-Yu
Dorans, Kimberly
Chung, Katherine Minjee
Bhutkar, Arjun
Hong, Erin
Jacks, Tyler E.
Date Issued
October 2017
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Muzumdar, Mandar Deepak et al. “Survival of Pancreatic Cancer Cells Lacking KRAS Function.” Nature Communications 8, 1 (October 2017): 1090 © 2017 The Author(s)
Version
Final published version
Abstract
Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. Here we model complete KRAS inhibition using CRISPR/Cas-mediated genome editing and demonstrate that KRAS is dispensable in a subset of human and mouse PDAC cells. Remarkably, nearly all KRAS deficient cells exhibit phosphoinositide 3-kinase (PI3K)-dependent mitogen-activated protein kinase (MAPK) signaling and induced sensitivity to PI3K inhibitors. Furthermore, comparison of gene expression profiles of PDAC cells retaining or lacking KRAS reveal a role of KRAS in the suppression of metastasis-related genes. Collectively, these data underscore the potential for PDAC resistance to even the very best KRAS inhibitors and provide insights into mechanisms of response and resistance to KRAS inhibition.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41467-017-00942-5